Making Medicine

The Faster Clinical Trials Act, MFN Fallout in Europe, and October’s Biotech Numbers

68 views · 22h ago · 16:52

What’s moving in biotech policy right now? In this Headlines episode of Making Medicine, host John Stanford runs through the month’s top stories shaping how medicines are discovered, developed, and delivered in America. Leading the headlines is the Faster Clinical Trials Act, a new bipartisan proposal to modernize clinical trials, reduce regulatory delays, and speed up drug development.

Topics: Election 2026: What's Next for Biotech? · Faster Clinical Trials Act: Bipartisan FDA Reform · Five Proposed Clinical Trial Reforms · How Faster Trials Could Strengthen Biotech Investment · MFN Drug Pricing and Global Drug Launches · Roche and Novartis: Rethinking European Markets

Inside the COINS Act: How Treasury’s China Rule Could Reshape Drug Development

420 views · 1w ago · 53:18

Guest: Max Bayer

Could Treasury’s proposed COINS Act rule make it harder for American patients to get promising new medicines? The proposed regulations would restrict a broad range of transactions with Chinese companies. That could change how U.S. biotech companies partner, invest, and bring new therapies to American patients. But how far does the rule actually reach?

Topics: FDA Reform and Other Policy Headlines · Meet Max Bayer of Endpoints News · Why China Biotech Became a Major Washington Story · COINS Act and BINSA: Competing Policy Approaches · Breaking Down Treasury’s Proposed Regulations · First Reaction: How Tough Are the Biotech Rules?

Myths vs. Facts: China, Biotech, and National Security

665 views · 2w ago · 31:20

Are American biotech companies really sending $120 billion to China? And could restricting U.S. investment weaken America's position in the global biotech industry? As Washington debates biotechnology investment restrictions and national security, Making Medicine host John Stanford examines five common claims shaping the conversation about China, pharmaceutical innovation, and American competitiveness.

Topics: Understanding the $120 Billion Headline · How Biotech Licensing Deals Work · Myth 2: American Investment Must Stay in America · U.S. Biotech and Chinese Drug Discoveries · Myth 3: Cutting Off Investment Will Stop China · China's Long-Term Biotech Strategy

Biotech Boom, Drug Lag: Japan's Innovation Paradox

443 views · 3w ago · 47:57

Guest: Michael Gutbrod

Japan has many of the ingredients of a world-class biotechnology ecosystem: leading scientific research, Nobel Prize-winning discoveries, and growing investment. Yet many innovative medicines reach Japanese patients later than in other markets, and some never launch at all.

Topics: Japan's Emerging Biotech Ecosystem · Inside BioLabs Tokyo · Why Investors Are Looking at Japan · Government Funding and AMED · Japan's Scientific Strengths · Cultural Challenges for Biotech Startups

Ohio’s Biotech Boom: Gene Therapy, Investment & the Race with China

2.8K views · 4w ago · 33:00

Guests: Ohio’s Biotech Boom, Eddie Pauline

Ohio is emerging as a major U.S. life sciences hub, with growing investment in biotech, gene therapy, biomanufacturing and pharmaceutical innovation. But what does it take to build a competitive biotech ecosystem outside traditional hubs like Boston and San Francisco?

Topics: America’s Emerging Biotech Hubs · GLOBE Drug Pricing & MFN Policy · Meet Eddie Pauline · Why Ohio Is Becoming a Biotech Hub · Gene Therapy & Ohio Innovation · NIH Funding & Life Sciences Policy

AI in Drug Discovery: What Works, What’s Hype & What Comes Next

5.8K views · 1mo ago · 48:08

Guest: Dr. Thomas Kaiser

Artificial intelligence could transform drug discovery and biotech, but not necessarily in the ways the biggest AI predictions suggest. Where can AI actually make drug development faster and more efficient, and where does the hype collide with the realities of biology?

Topics: AI, Biotech & the Future of Drug Discovery · From Biotech Founder to Biotech Investor · Avicenna's ALS Drug & First-in-Human Trials · Building a Biotech With $25 Million · How Avicenna Uses AI Differently · 11 Compounds, 2 Clinical Candidates